Ayşe Seza İNAL, Selçuk NAZİK, Aslıhan CANDEVİR, Behice KURTARAN, Yeşim TAŞOVA, Hasan Salih Zeki AKSU

Toksoplazma ensefaliti: serebral kitle ile başvuran HIV/AIDS olgusu

Toksoplazma ensefaliti CD4+ T lenfosit sayısı azalmış olan hastalarda, Toxoplasma gondii’nin latent halde bulunan doku kistlerinin reaktivasyonu ile ortaya çıkan fırsatçı bir enfeksiyondur. Toksoplazma ensefaliti, insan immün yetmezlik virüsü enfeksiyonu ve kazanılmış immün yetmezlik sendromu olan hastalarda, santral sinir sistemi tutulumunun başta gelen nedenlerindendir. Bu yazıda , ateş ve nörolojik bulgularla başvuran, radyolojik incelemeler sonucunda saptanan serebral kitlenin etiyolojisi araştırılırken immün yetmezlik virüsü enfeksiyonu tanısı konan ve antiretroviral ve antiprotozoal tedavi ile tam iyileşme sağlanan bir toksoplazma ensefaliti olgusu sunulmuştur.

Toxoplasma encephalitis: an HIV/AIDS patient with cerebral mass

Toxoplasmic encephalitis is an opportunistic infection, which develops as a result of reactivation of the latent tissue cysts of Toxoplasma gondii in patients with reduced CD4+ T lymphocytes. Amongst patients with human immunodeficiency virus or acquired immunodeficiency syndrome, toxoplasmic encephalitis is one of the leading causes of the intracerebral involvement. In this report, we present a toxoplasmic encephalitis case, who has admitted with neurological symptoms and fever. The patient was identified human immunodeficiency virus positive while he was under investigation for cerebral mass lesion, The patient has fully recovered by antiprotozoal and antiretroviral therapy.

Keywords:

HIV, AIDS, encephalitis, toxoplasma gondii, toxoplasmosis.,

PDF

___

1. Luft BJ, Hafner R, Korzun AH, Leport C, Antoniskis D, Bosler EM et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med. 1993;329:995-1000.
2. Belanger F, Derouin F, Grangeot-Keros L, Meyer L. Incidence and risk factors of toxoplasmosis in a cohort of human immunodeficiency virus-infected patients: 1988-1995. HEMOCO and SEROCO Study Groups. Clin Infect Dis. 1999;28:575-81.
3. Siddiqi OK, Koralnik IJ. Neurologic diseases caused by Human Immunodeficiency Virus Type 1 and opportunistic infections. In Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases, Bennett JE, Dolin R, Blaser MJ (editors). 8th ed. Philadelphia: Saunders. 2015:1574-89.
4. Kiderlen TR, Liesenfeld O, Schurmann D, Schneider T. Toxoplasmic encephalitis in AIDS-patients before and after introduction of highly active antiretroviral therapy (HAART). Eur Clin Microbiol Infect Dis. 2011;30:1521-5.
5. Dai L, Mahajan SD, Guo C, Zhang T, Wang W, Li T, et al. Spectrum of central nervous system disorders in hospitalized HIV/AIDS patients (2009- 2011) at a major HIV/AIDS referral center in Beijing, China. J Neurol Sci. 2014;342:88-92.
6. UK Collaborative HIV Cohort (CHIC) Study Steering Committee, Garvey L, Winston A, Walsh J, Post F, Porter K et al. HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol. 2011;18:527- 34.
7. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis. 1992;15:211-22.
8. Weiss LM, Dubey JP. Toxoplasmosis: a history of clinical observations. Int J Parasitol. 2009;39:895-901.
9. Montoya JG, Boothroyd JC, Kovacs JA. Toxoplasma gondii, In: Bennett JE, Dolin R, Blaser MJ (eds). In: Bennett JE, Dolin R, Blaser MJ (eds). Principles and Practice of Infectious Diseases. Saunders, Philadelphia. 2015;3122-3153.
10. Gencer M, Cevizci S, Saçar S, Vural A, Çakır Güngör AN, Uysal A et al. Çanakkale Onsekiz Mart Üniversitesi Tıp Fakültesi Hastanesi Obstetri Polikliniğine müracaat eden gebelerde Anti- Toxoplasma gondii antikorlarının dağılımı ve risk faktörlerinin irdelenmesi. Turkiye Parazitol Derg. 2014;38:76-80.
11. Altuntaş Aydın Ö, Kumbasar Karaosmanoğlu H, Korkusuz R, Nazlıcan Ö. HIV/AIDS hastalarında Toxoplasma gondii seroprevalansı. Turkiye Parazitol Derg. 2014;35:65-7.
12. Türkiye’de AIDS vakalarının dağılımı (Haziran 2014). Hacettepe Üniversitesi HIV/AIDS Tedavi ve Araştırma Merkezi (HATAM) http://www.hatam.hacettepe.edu.tr/veriler_Haziran _2014.pdf Son Erişim Tarihi: 8 Ağustos 2016. 13. Haverkos HW. Assessment of therapy for Toxoplasma encephalitis. The TE Study Group. Am J Med 1987;82: 907-14.
14. Antinori A, Larussa D, Cingolani A, Lorenzini P, Bossolasco S, Finazzi MG, et al. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis. 2004;39:1681-91.
15. Olariu TR, Remington JS, McLeod R, Alam A, Montoya JG. Severe congenital toxoplasmosis in the United States: clinical and serologic findings in untreated infants. Pediatr Infect Dis. J 2011;30:1056– 61.
16. Dubey JP, Lago EG, Gennari SM, Su C, Jones JL. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology. 2012;139:1375-424.
17. Shankar SK, Mahadevan A, Satishchandra P, Kumar RU, Yasha TC, Santosh V, et al. Neuropathology of HIV/AIDS with an overview of the Indian scene. Indian J Med Res. 2005;121:468-88.
18. Kurne A, Özkaya G, Karlıoğuz K, Shorbagi A, Ustaçelebi Ş, Karabudak R, et al. HIV pozitif beş olguda serebral toksoplazmozisin renkli kliniği: Pandora’nın kutusundan çıkanlar. Mikrobiyol Bült. 2006;40:85-92.
19. Torre D, Speranza F, Martegani R, Zeroli C, Banfi M, Airoldi M. A retrospective study of treatment of cerebral toxoplasmosis in AIDS patients with trimethoprim-sulphamethoxazole. J Infect. 1998;37:15-8.
20. Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings.) Cochrane Database Syst Rev. 2006;19:CD005420.